You are here

  • Home
  • Online First
  • Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?

Article Text

Article menu

other Versions

Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Intensive glucose-lowering therapy in people with type 2 diabetes: what do we learn from a new meta-analysis of randomised controlled trials?
  1. Fiona Turnbull,
  2. Sophia Zoungas
  1. 1Cardiovascular Division, The George Institute for Global Health, Sydney, Australia
  1. Correspondence to Fiona Turnbull
    Cardiovascular Division, The George Institute for Global Health, Level 10, KGV Building, RPAH, Missenden Rd, Camperdown, New South Wales 2050, Australia; fturnbull{at}george.org.uk

https://doi.org/10.1136/ebmed-2011-100230

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169.OpenUrlAbstract/FREE Full Text

    Context

    The majority of patients with diabetes continue to die from cardiovascular causes. The degree to which improved glucose control could help to address this risk has been examined in recent large trials1,–,3 comparing intensive with usual blood glucose-lowering strategies. This meta-analysis pools the findings from these recent trials as well as several older trials with the aim of defining the effects of intensive control on mortality, cardiovascular events and microvascular events in patients with type 2 diabetes.

    Methods

    Boussageon et al conducted a pooled analysis using published data from 13 trials selected on the basis of having an intensive glucose-lowering treatment arm compared with either a ‘standard’ …

    View Full Text

    Footnotes

    • Competing interests None.